Bayer AG: New stakes in stem cells
January 2011. Andreas Busch, responsible for Global Drug Discovery in Bayer Pharma AG (formerly Bayer HealthCare) explains why his company opted for cancer stem cells instead of pursuing regenerative medicine. A first hand account exclusively for B2Bioworld’s readers. Insights for business development with biotech companies and options for venture capital. Includes Bayer's research pipeline (as of Dec 2010).Reading time: 4 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Strategic ambiguities with "stem cells"
Bernd Kirschbaum,Global Discovery and Early Development Merck Serono on strategic ambiguities in technology development
Boehringer Ingelheim: Embryonic stem cells and animal models
Andreas Barner, Chairman Boehringer Ingelheim and Head of Pharma Research